InflaRx

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell InflaRx and other ETFs, options, and stocks.

About IFRX

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab.

CEO

Niels Christoph Riedemann

CEONiels Christoph Riedemann

Employees

Employees74

Headquarters

Jena, Thueringen

HeadquartersJena, Thueringen

Founded

2007

Founded2007

Employees

Employees74

IFRX Key Statistics

Market cap

58.40M

Market cap58.40M

Price-Earnings ratio

-0.83

Price-Earnings ratio-0.83

Dividend yield

—

Dividend yield—

Average volume

545.88K

Average volume545.88K

High today

$0.88

High today$0.88

Low today

$0.8311

Low today$0.8311

Open price

$0.85

Open price$0.85

Volume

177.36K

Volume177.36K

52 Week high

$2.82

52 Week high$2.82

52 Week low

$0.7113

52 Week low$0.7113

IFRX News

TipRanks 4d

InflaRx Receives Nasdaq Deficiency Notice for Share Price

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

Analyst ratings

86%

of 7 ratings

Buy

85.7%

Hold

14.3%

Sell

People also own

Based on the portfolios of people who own IFRX. This list is generated using Robinhood data, and it’s not a recommendation.